%0 Journal Article %T BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy %A Yau, Edwin H. %J Precision Cancer Medicine %D 2021 %B 2021 %9 %! BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy %K %X %U https://pcm.amegroups.org/article/view/5969 %V 4 %P %@ 2617-2216